Pharmacotherapy of obesity: an update on the available medications and drugs under investigation

M Chakhtoura, R Haber, M Ghezzawi, C Rhayem… - …, 2023 - thelancet.com
Obesity is an epidemic and a public health threat. Medical weight management remains one
of the options for the treatment of excess weight and recent advances have revolutionized …

Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction

KC Maki, CF Kirkpatrick, DB Allison… - Expert Review of …, 2023 - Taylor & Francis
Introduction Obesity is highly prevalent in the US and is associated with an increased risk of
major adverse cardiovascular events (MACE). Modalities for the management of obesity …

Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history

A Avogaro, SV de Kreutzenberg, ML Morieri… - The Lancet Diabetes & …, 2022 - thelancet.com
The life history theory assumes that all organisms are under selective pressure to harvest
external resources and allocate them to maximise fitness: only organisms making the best …

Body Mass Index, Obesity, and Mortality—Part II: Weight Loss and Weight Cycling

LM Sanders, LM Mestre, K Ejima, T Mehta… - Nutrition …, 2023 - journals.lww.com
The relationship of obesity with mortality rate, and subsequently, the impact of weight loss on
mortality, has been questioned by researchers for many years. Although weight loss in an …

Intragastric balloon significantly improves metabolic parameters at 6 months: a meta-analysis

RH Shah, S Vedantam, S Kumar, S Amin, M Pearlman… - Obesity Surgery, 2023 - Springer
Introduction It is estimated that by 2030, 38% of the world population will be overweight, and
another 20% will be people with obesity. Intragastric balloons (IGBs) are an option in …

[HTML][HTML] The weight reduction mediated by anti-obesity medication and the cardiovascular outcome

Y Guo, C Lin, X Cai, H Wu, J Yan, Z Li, R Jiao, S Bai… - Iscience, 2024 - cell.com
The association between anti-obesity medications (AOMs) as well as their weight-loss
effects and cardiovascular outcomes need to be comprehensively investigated. We …

Médicaments anti-obésité: leçons des échecs pour l'avenir

AJ Scheen - Médecine des Maladies Métaboliques, 2021 - Elsevier
Résumé Médecins et patients obèses rêvent d'une approche pharmacologique efficace et
sûre pour traiter l'obésité. Hélas, la plupart des médicaments anti-obésité testés depuis les …

Pharmacotherapy for Obesity: Recent Evolution and Implications for Cardiovascular Risk Reduction

KC Maki, CF Kirkpatrick, DB Allison… - … Outcomes Research: A …, 2024 - Springer
Introduction: Obesity is highly prevalent in the US and is associated with an increased risk of
major adverse cardiovascular events (MACE). Modalities for the management of obesity …

Implementing the 5A's of Obesity Management in Primary Care

HH Rowell - 2024 - scholarcommons.sc.edu
Abstract Problem Statement: The prevalence of obesity continues to increase globally, with
greater prevalence in the southern United States, resulting in higher costs to the healthcare …

[HTML][HTML] Summary of Data Extracted from Systematic Reviews and Other Reviewed Literature

National Academies of Sciences … - … Reference Intakes for …, 2023 - ncbi.nlm.nih.gov
of Data Extracted from Systematic Reviews and Other Reviewed Literature - Dietary Reference
Intakes for Energy - NCBI Bookshelf US flag An official website of the United States government …